Comparative Pharmacology
Head-to-head clinical analysis: IFOSFAMIDE versus TEPYLUTE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: IFOSFAMIDE versus TEPYLUTE.
IFOSFAMIDE vs TEPYLUTE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Prodrug activated by cytochrome P450 to cytotoxic metabolites (4-hydroxyifosfamide, acrolein, and ifosforamide mustard) that alkylate DNA by cross-linking guanine bases, inhibiting DNA replication and transcription.
Progestin that transforms endometrium from proliferative to secretory phase, inhibits gonadotropin secretion, and increases cervical mucus viscosity.
1.2 g/m² IV over 2 hours daily for 5 consecutive days every 3 weeks, or 5 g/m² IV as a 24-hour continuous infusion every 3 weeks. Administer with mesna and vigorous hydration.
100 mg orally once daily
None Documented
None Documented
Terminal half-life: 4-7 hours for parent drug; active metabolite 4-desulfonate has half-life ~12-15 hours. Clinical context: Prolonged with renal impairment.
Clinical Note
moderateIfosfamide + Digoxin
"Ifosfamide may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateIfosfamide + Digitoxin
"Ifosfamide may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateIfosfamide + Deslanoside
"Ifosfamide may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateIfosfamide + Acetyldigitoxin
"Ifosfamide may decrease the cardiotoxic activities of Acetyldigitoxin."
Terminal elimination half-life is 4-6 hours in healthy adults; prolonged to 10-15 hours in severe renal impairment.
Primarily renal: 50-60% excreted unchanged in urine. Biliary/fecal excretion is minimal (<5%).
Primarily renal (70-80% unchanged) and fecal (15-20% as metabolites).
Category D/X
Category C
Alkylating Agent
Alkylating Agent